This study looks at new ways to detect early signs of **Parkinson's Disease** using a special test called the **α-Synuclein Ultrafine Fluorescence Detection Method**. This test checks body fluids like saliva, urine, and blood, as well as the skin, for clues of the disease. Unlike a brain biopsy, which is more invasive, this method only requires a tiny skin sample, making it safer and less painful. The study aims to improve early diagnosis, which can help reduce costs and improve care. **Key Points:** - **Study Duration:** This study is observational, meaning it does not involve treatment, but only observation of participants. - **Participation Requirements:** Participants include patients with Parkinson's as well as healthy individuals, with age and gender matched. - **Benefits and Risks:** The test is minimally invasive, reducing the risks compared to traditional methods. Participants should not have other severe cognitive or neurodegenerative issues. This research can help in early diagnosis, potentially making treatments more effective and lessening the burden on patients and healthcare systems.